These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16440929)

  • 1. Quinupristin-dalfopristin-induced reticulocytopenic anemia.
    Chan-Tack KM; Mehta S
    South Med J; 2005 Dec; 98(12):1226-7. PubMed ID: 16440929
    [No Abstract]   [Full Text] [Related]  

  • 2. Anemia and reversible reticulocytopenia associated with extended quinupristin/dalfopristin.
    Evans PC; Almas JP; Criddle FJ
    Ann Pharmacother; 2004 Apr; 38(4):720-1. PubMed ID: 14766992
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe reversible reticulocytopenic anemia associated with quinupristin/dalfopristin RP59500 therapy.
    Launay O; Chemlal K; Andrieu V; Carbon C
    Clin Infect Dis; 1997 Jul; 25(1):156. PubMed ID: 9243054
    [No Abstract]   [Full Text] [Related]  

  • 4. Quinupristin/dalfopristin-induced Sweet's syndrome.
    Choi HS; Kim HJ; Lee TH; Lee SH; Lee TW; Ihm CG; Kim MJ
    Korean J Intern Med; 2003 Sep; 18(3):187-90. PubMed ID: 14619389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quinupristin and dalfopristin.
    Am J Health Syst Pharm; 1999 Dec; 56(24):2530-1. PubMed ID: 10613369
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety and tolerability of quinupristin/dalfopristin: administration guidelines.
    Rubinstein E; Prokocimer P; Talbot GH
    J Antimicrob Chemother; 1999 Sep; 44 Suppl A():37-46. PubMed ID: 10511396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyponatremia associated with quinupristin-dalfopristin.
    Cole RP; Roberts WD; Cheng MD
    Ann Intern Med; 2000 Sep; 133(6):485. PubMed ID: 10975979
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort.
    Linden PK; Pasculle AW; McDevitt D; Kramer DJ
    J Antimicrob Chemother; 1997 May; 39 Suppl A():145-51. PubMed ID: 9511079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.
    Fagon J; Patrick H; Haas DW; Torres A; Gibert C; Cheadle WG; Falcone RE; Anholm JD; Paganin F; Fabian TC; Lilienthal F
    Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):753-62. PubMed ID: 10712318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.
    Lamb HM; Figgitt DP; Faulds D
    Drugs; 1999 Dec; 58(6):1061-97. PubMed ID: 10651391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance.
    Chong YP; Lee SO; Song EH; Lee EJ; Jang EY; Kim SH; Choi SH; Kim MN; Jeong JY; Woo JH; Kim YS
    Scand J Infect Dis; 2010 Jul; 42(6-7):491-9. PubMed ID: 20524781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans.
    Bergeron M; Montay G
    J Antimicrob Chemother; 1997 May; 39 Suppl A():129-38. PubMed ID: 9511077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinupristin-dalfopristin use in children is associated with arthralgias and myalgias.
    Gupte G; Jyothi S; Beath SV; Kelly DA
    Pediatr Infect Dis J; 2006 Mar; 25(3):281. PubMed ID: 16511403
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetics of quinupristin/ dalfopristin in patients with severe chronic renal insufficiency.
    Chevalier P; Rey J; Pasquier O; Leclerc V; Baguet JC; Meyrier A; Harding N; Montay G
    Clin Pharmacokinet; 2000 Jul; 39(1):77-84. PubMed ID: 10926351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of quinupristin/dalfopristin.
    Bearden DT
    Clin Pharmacokinet; 2004; 43(4):239-52. PubMed ID: 15005638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with quinupristin-dalfopristin as rescue treatment of critically ill patients infected with methicillin-resistant staphylococci.
    Sander A; Beiderlinden M; Schmid EN; Peters J
    Intensive Care Med; 2002 Aug; 28(8):1157-60. PubMed ID: 12185441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between myalgias/arthralgias occurring in patients receiving quinupristin/dalfopristin and biliary dysfunction.
    Raad I; Hachem R; Hanna H
    J Antimicrob Chemother; 2004 Jun; 53(6):1105-8. PubMed ID: 15128724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of vancomycin-resistant Enterococcus faecium infections with an investigational streptogramin antibiotic (quinupristin/dalfopristin): a report of fifteen cases.
    Dever LL; Smith SM; Dejesus D; Masurekar M; Patel D; Kaminski ZC; Johanson WG
    Microb Drug Resist; 1996; 2(4):407-13. PubMed ID: 9158811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quinupristin/dalfopristin, a new addition to the antimicrobial arsenal.
    Johnson AP; Livermore DM
    Lancet; 1999 Dec; 354(9195):2012-3. PubMed ID: 10636359
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of the quinupristin/dalfopristin breakpoints for Enterococcus faecium.
    Hammerum AM; Agersø Y; Garcia-Migura L; Mette Seyfarth A; Porsbo LJ; Emborg HD; Bogø Jensen L
    Int J Antimicrob Agents; 2009 Sep; 34(3):288-90. PubMed ID: 19409762
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.